Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Other Non-Current Assets (2023 - 2025)

CG Oncology's Other Non-Current Assets history spans 3 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 1685.11% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, up 1685.11%, while the annual FY2025 figure was $1.7 million, 1685.11% up from the prior year.
  • Other Non-Current Assets reached $1.7 million in Q4 2025 per CGON's latest filing, up from $114000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $4.7 million in Q4 2023 to a low of $53000.0 in Q1 2024.
  • Average Other Non-Current Assets over 3 years is $861111.1, with a median of $114000.0 recorded in 2025.
  • Peak YoY movement for Other Non-Current Assets: tumbled 97.99% in 2024, then soared 1685.11% in 2025.
  • A 3-year view of Other Non-Current Assets shows it stood at $4.7 million in 2023, then crashed by 97.99% to $94000.0 in 2024, then skyrocketed by 1685.11% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Other Non-Current Assets are $1.7 million (Q4 2025), $114000.0 (Q3 2025), and $522000.0 (Q2 2025).